Please assess the completion status of the following clinical trial:

Trial Title: FACTO Study (Foster® As Complete Treatment Option)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Asthmatic patients will be enrolled at Visit 1 into the run-in period if they meet all of the following criteria:~1. Written informed consent obtained~2. Adult male and female (≥18 and ≤65 years)~3. Clinical diagnosis of controlled asthma according to Global Strategy for Asthma Management and Prevention (GINA) revised version 2007 in the previous week before study entry:~   * no daytime symptoms (twice or less/week)~  * no limitations of activities~  * no nocturnal symptoms/awakenings~  * no need for reliever/rescue medications (twice or less/week)~  * lung function (FEV1) \> 80% predicted or personal best (if known)~4. Patients treated with fluticasone 500 µg + salmeterol 100 µg daily for ≥ 4 weeks~5. A co-operative attitude and ability to correctly use the device and to complete the diary cards.~Exclusion Criteria:~Patients will not be enrolled at visit 1 into the run-in period if they meet any of the following criteria:~1. Inability to carry out pulmonary function testing;~2. Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) as defined by the National Heart Lung and Blood Institute/World Health Organisation (NHLBI/WHO) Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines;~3. History of near fatal asthma;~4. Evidence of severe asthma exacerbation or symptomatic infection of the lower airways in the previous six months;~5. Three or more courses of oral corticosteroids or hospitalisation due to asthma during the previous 6 months;~6. Patients treated with long-acting β2-agonists (LABAs) other than salmeterol, anticholinergics, and leukotriene antagonists during the previous 4 weeks;~7. Current smokers or recent (less than one year) ex-smokers defined as smoking at least 15 packs/year;~8. Clinically significant or unstable concurrent disease : e.g. uncontrolled hyperthyroidism, uncontrolled diabetes mellitus or other endocrine disease; significant hepatic impairment; significant renal impairment; significant other pulmonary disease; cardiovascular disease; gastrointestinal disease; neurological disease; haematological disease, autoimmune disorders, that may interfere with patient's safety, compliance, or study evaluations, according to the investigator's opinion;~9. Patients with a serum potassium value ≤ 3.5 mEq/L~10. Patients with QTc interval (Bazett's formula) higher than 450 msec at screening visit 1;~11. Cancer or any chronic diseases with prognosis \< 2 years;~12. Female subjects: pregnant or with active desire to be pregnant, lactating mother or lack of efficient contraception in a subject with child-bearing potential (i.e. contraceptive methods other than oral contraceptives, IUD, tubal ligature). A pregnancy test in urine is to be carried out in women of a fertile age at screening~13. Significant alcohol consumption or drug abuse;~14. Patients treated with beta-blockers as regular use;~15. Patients treated with monoamine oxidase inhibitor, tricyclic antidepressants and Selective Serotonin Re-uptake Inhibitors (SSRIs), unless already taken at stable doses at the screening visit~16. Allergy, sensitivity or intolerance to study drugs and/or study drug formulation ingredients;~17. Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study;~18. Patients who received any investigational new drug within the last 12 weeks;~19. Patients with asthma exacerbations during the run-in period will also be excluded from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): CHF1535 (beclometasone dipropionate plus formoterol, 400/24 µg daily)
- 2 (Type: ACTIVE_COMPARATOR): Seretide® Diskus® (fluticasone plus salmeterol, 500/100 µg /daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).